Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Open-label Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)
Conditions
Interventions
Azacitidine
Cusatuzumab
Locations
73
Australia
St Vincents Hospital Sydney
Darlinghurst, Australia
St Vincents Hospital Melbourne
Fitzroy, Australia
Peter MacCallum Cancer Institute
Melbourne, Australia
Royal Perth Hospital
Perth, Australia
Westmead Hospital
Westmead, Australia
Wollongong Hospital
Wollongong, Australia
Start Date
May 6, 2021
Primary Completion Date
April 19, 2022
Completion Date
January 28, 2025
Last Updated
May 20, 2022
NCT06303193
NCT06847867
NCT06439199
NCT07216443
NCT06656494
NCT05588154
Lead Sponsor
Janssen Research & Development, LLC
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions